CS MEDICA A/S announced the signing of a Letter of Intent with GP Europe Holding B.V. This LOI marks the preliminary step towards establishing a potentially transformative partnership focused on supply chain enhancement and distribution agreements, paving the way for possible investment or merger scenarios. Under the terms of the LOI, both companies aim to capitalize on their respective strengths to foster innovation and enhance market offerings. Key aspects of this collaboration include: Joint Research & Development: CS MEDICA and GP Holding aim to engage in joint R&D efforts to create pioneering products that integrate GP Holding's expertise in hemp-based products with CS MEDICA's advanced pharmaceutical research capabilities and CBD technology.

Product Portfolio Expansion: The partnership aims to integrate CS MEDICA's CBD-infused substance-based medical devices into GP Holding's product portfolio. This strategic move is designed to broaden consumer choices and enhance market penetration by cross-promoting products across diverse customer bases. Strategic Partnership Development: The collaboration aims to strengthen both companies' market positions by optimizing production capacities and improving supply chain efficiencies, which are crucial for scaling operations and achieving economic benefits.